Skip to content

Should You Take TMG With NMN?

Does NMN require TMG? Methylation research, a recruiting combination trial, homocysteine findings and betaine’s dose-specific lipid tradeoffs.

By Marcus HaleLongevity Research Editor
Updated

4 min read · 15 sources

On this page

TMG has not been established as a necessary companion to NMN. It can affect homocysteine metabolism, but that does not show that an NMN supplement creates a deficiency or that adding TMG improves health. Calling the combination “insurance” goes beyond the evidence.

The distinction matters when buying a bundle. First decide whether NMN’s human evidence supports your goal; then assess the additional ingredient on its own merits. The NAD+ dosage guide describes research doses, not a formula for matching milligrams of NMN and TMG.

Affiliate partner

RxSpan MD

Physician-led NAD+ & longevity telehealth

See RxSpan MD

What TMG does in the methylation pathway

TMG means trimethylglycine, also called betaine. Betaine can donate a methyl group in the conversion of homocysteine to methionine. NMN contributes to NAD+ metabolism; nicotinamide generated through NAD+ turnover can be methylated by the enzyme NNMT 1215. These connected pathways explain the proposed pairing, but a shared pathway does not establish that one supplement requires another.

Methylated nicotinamide products were measured in a small human NAD+ infusion study. High-dose nicotinamide also altered metabolic and epigenetic measurements in developing rats 45. Neither experiment tested whether ordinary oral NMN use causes a clinically important shortage that TMG corrects. Route, compound, dose and population all matter.

The methyl-drain hypothesis

NMN raises NAD+

Precursor; reliably increases blood NAD+

NAD+ → nicotinamide

Breakdown product to be cleared

NNMT methylates it

Uses a methyl group from SAM; excreted in urine

Possible methyl demand

A clinically important NMN-related deficit is not established

Betaine donates methyl

Does not establish benefit from adding it to NMN

A metabolic pathway explains a hypothesis. It does not establish that an NMN user has a deficiency or needs a particular TMG dose.

What human precursor studies can tell us

The older NMN studies frequently cited for this combination tested NMN itself: one involved single doses in ten men 2; another studied 1,250 mg daily for four weeks in 31 adults 3; a dose-ranging trial followed 80 adults for 60 days 1. They provide bounded tolerability observations. They were not NMN-versus-NMN-plus-TMG trials, and an adverse-event summary cannot establish that every methylation-related outcome was measured or unchanged.

There is more direct methylation information for NR, which is a different precursor. In NR-SAFE, 20 people with Parkinson’s disease received NR or placebo for four weeks. The NR dose was 3,000 mg daily. Serum homocysteine rose slightly early in treatment, while the measured methyl-donor pool remained intact 13. This is useful evidence against treating methylated breakdown products as automatic proof of depletion. It also does not justify high-dose self-treatment or establish an NMN/TMG ratio. See NMN versus NR for why their findings should not be merged.

A combination trial is registered, but results are not posted

As checked on October 28, 2026, ClinicalTrials.gov lists NCT07144527 as recruiting, with no posted results. Its four arms use two crossover sequences for NMN with TMG versus placebo and two for NMN alone versus placebo. This is not a design in which every participant receives all three formulations. Fasting homocysteine is among the listed measurements. The record was last updated October 7, 2026 14.

A relevant trial is registered, without results that establish benefit. A protocol is a plan, not a positive finding. Its eventual results will need assessment for the actual comparison, participant characteristics, missing data, harms and clinical outcomes.

Lower homocysteine is not the same as a proven health benefit

Betaine has lowered homocysteine in human experiments, but effects depend on dose and setting. In a ten-person acute crossover study, 3 g and 6 g lowered homocysteine whereas 1 g did not. An eight-man study found effects under a methionine challenge that should not be confused with treating routine NMN use 67. Observational associations involving betaine, folate and homocysteine add context; they cannot establish that a supplement prevents cardiovascular events 89.

The practical question is why a particular person has an abnormal result and whether changing it with a particular treatment improves outcomes. Buying a stack does not answer either question. Our B12 guide separates correcting a defined nutrient problem from adding an NAD+ product for general wellness.

The lipid findings are mixed, not a guaranteed small tradeoff

A pooled analysis of controlled studies found that 6 g of betaine daily for six weeks raised LDL cholesterol and triglycerides relative to placebo 10. This is a reason to examine the dose and context; it does not quantify the risk of every lower-dose retail bundle.

A separate six-month study in 63 healthy volunteers using 4 g daily concluded that betaine did not change the lipid profile overall, with weak homocysteine lowering 11. It should not be cited as confirming the same unfavorable lipid result. The evidence supports a qualified discussion, not “TMG is risk-free” or “TMG always raises cholesterol.”

What the human evidence supports

  • Betaine affects homocysteineModerate evidence

    Human trials show dose- and context-dependent effects.

  • Methylated NAD-related metabolitesModerate evidence

    Measurable metabolites are not automatic evidence of methyl-donor depletion.

  • Routine TMG requirement with NMNNone evidence

    No established clinical requirement or validated pairing ratio.

  • Benefit from NMN plus TMGNone evidence

    Relevant registered trial is recruiting without posted results in October 2026.

  • Uniform safety or lipid effectWeak evidence

    Higher-dose studies report differing lipid findings; assess the actual product and person.

Registered research, biomarkers, clinical benefit and harms are separate questions.

TMG supplements and prescription betaine have different uses

Betaine anhydrous is also the active ingredient in the prescription medicine Cystadane, used for specified forms of homocystinuria. That approved indication is separate from adding a retail TMG supplement to NMN 15. It is inaccurate to say that betaine has no approved medical use.

The prescription label includes a specific warning about high methionine and cerebral edema in patients with CBS deficiency. That warning concerns a defined disease and treatment context; it is not evidence that an ordinary NMN/TMG bundle causes the same event in everyone. It does show why an inherited metabolic disorder needs specialist care rather than an online “methylation” protocol.

How to assess a bundle before buying

There is no established NMN-to-TMG dose ratio for preventing a demonstrated NMN-related deficiency. A larger NMN amount is not a reason to automatically add more TMG. If homocysteine is elevated, ask the treating clinician to evaluate the cause and the relevant treatment rather than assuming NMN caused it.

Review each ingredient and medication together. The NMN medication guide covers the limits of interaction data, and the magnesium combination guide explains why a different add-on needs a different assessment. The same standard applies to the NMN/resveratrol pairing and NMN with metformin: plausible biology does not establish a necessary combination.

If cost, side effects or uncertain benefit are the concern, adding products can make the decision harder to evaluate. Consider why people stop NMN, the broader NAD+ therapy evidence and the clearly disclosed product terms in our NAD+ provider comparison before expanding a stack.

Frequently asked questions

Do you need to take TMG with NMN?

A routine requirement has not been established. The proposed methylation mechanism does not demonstrate a deficiency in an individual NMN user, and no validated NMN-to-TMG ratio is available.

Has NMN with TMG been studied in people?

As checked October 28, 2026, NCT07144527 is recruiting without posted results. Its four arms separately cross NMN/TMG or NMN alone with placebo, and include homocysteine measurements. Registration and planned measurements do not establish benefit.

Does TMG lower homocysteine?

It has done so in human experiments, but effects depend on dose and context. Lowering this biomarker does not by itself demonstrate prevention of cardiovascular disease or a need to pair it with NMN.

Can TMG affect cholesterol?

A pooled six-week analysis at 6 g daily found increased LDL cholesterol and triglycerides. A different six-month trial at 4 g daily found no overall lipid-profile effect. Neither result establishes the effect of every lower-dose bundle.

Is betaine an approved medicine?

Prescription betaine anhydrous, Cystadane, is approved for specified forms of homocystinuria. That indication and its specialist monitoring are separate from retail TMG marketed as an NMN companion.

References

  1. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  2. Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.. Endocrine Journal. https://pubmed.ncbi.nlm.nih.gov/31685720/
  3. Fukamizu Y, Uchida Y, Shigekawa A, et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/36002548/
  4. Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+.. Frontiers in Aging Neuroscience. https://pubmed.ncbi.nlm.nih.gov/31572171/
  5. Li D, Tian YJ, Guo J, et al. (2013). Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.. British Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/23768418/
  6. Atkinson W, Elmslie J, Lever M, Chambers ST, George PM (2008). Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects.. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/18326594/
  7. Schwab U, Törrönen A, Meririnne E, et al. (2006). Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans.. Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/16365055/
  8. Melse-Boonstra A, Holm PI, Ueland PM, Olthof M, Clarke R, Verhoef P (2005). Betaine concentration as a determinant of fasting total homocysteine concentrations and the effect of folic acid supplementation on betaine concentrations.. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/15941890/
  9. Holm PI, Ueland PM, Vollset SE, et al. (2005). Betaine and folate status as cooperative determinants of plasma homocysteine in humans.. Arteriosclerosis, Thrombosis, and Vascular Biology. https://pubmed.ncbi.nlm.nih.gov/15550695/
  10. Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB (2005). Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans.. PLoS Medicine. https://pubmed.ncbi.nlm.nih.gov/15916468/
  11. Schwab U, Alfthan G, Aro A, Uusitupa M (2011). Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects.. European Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/20978525/
  12. Sun WD, Zhu XJ, Li JJ, et al. (2024). Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target.. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/39312861/
  13. Berven H, Kverneng S, Sheard E, et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature Communications. https://www.nature.com/articles/s41467-023-43514-6
  14. Concordia University Chicago (2026). Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults (NCT07144527). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07144527
  15. Recordati Rare Diseases (2026). CYSTADANE: betaine anhydrous prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.